Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4314072)

Published in PLoS One on February 02, 2015

Authors

Maria L Knudsen1, Karl Ljungberg1, Roger Tatoud2, Jonathan Weber2, Mariano Esteban3, Peter Liljeström1

Author Affiliations

1: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
2: Imperial College London, Department of Infectious Diseases, Division of Medicine, Norfolk Place, London, United Kingdom.
3: Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.

Articles cited by this

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77

Innate recognition of viruses. Immunity (2007) 6.21

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58

Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol (1999) 2.95

Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39

Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25

Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 2.20

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine (1998) 1.74

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology (2006) 1.62

DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57

Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol (2006) 1.49

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines (2010) 1.31

Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J Virol (2005) 1.30

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22

Electroporation for DNA immunization: clinical application. Expert Rev Vaccines (2010) 1.21

PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J Gen Virol (2009) 1.18

Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol (2006) 1.15

Immunodominance: a pivotal principle in host response to viral infections. Clin Immunol (2012) 1.08

Semliki forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells. J Virol (2010) 1.07

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06

Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol (1997) 1.04

Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol (2012) 1.03

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol (2009) 1.01

Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One (2012) 0.96

Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon. Cancer Res (1984) 0.95

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One (2014) 0.94

Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine (2005) 0.94

The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis (2010) 0.93

Prime-boost immunization strategies against Chikungunya virus. J Virol (2014) 0.92

Predicting the impact of CD8+ T cell polyfunctionality on HIV disease progression. J Virol (2014) 0.89

HIV-1 vaccines: challenges and new perspectives. Hum Vaccin Immunother (2014) 0.89

Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol (2007) 0.88

Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine (2014) 0.87

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol (2005) 0.87

HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo. PLoS One (2013) 0.85

Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol (2010) 0.84

A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One (2012) 0.80

Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J (2011) 0.80

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One (2014) 0.79

Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines (2014) 0.79

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J Virol (2014) 0.79

Intradermal electroporation of RNA. Methods Mol Biol (2014) 0.78

The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon. PLoS One (2013) 0.77